Organigram Global Inc. (OGI) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low41.4·High41.4
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.50
↓-35% vs avg
5yr avg: 0.77
30Y Low0.4·High1.8
ROE
↑
-5.4%
↓+77% vs avg
5yr avg: -23.3%
30Y Low-166%·High15%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low2.5·High3.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OGI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Organigram Global Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $136M | $259M | $172M | $107M | $365M | $684M | $218M | $593M | — | — | — |
| Enterprise Value | $122M | $240M | $70M | $77M | $300M | $634M | $297M | $595M | — | — | — |
| P/E Ratio → | -9.76 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.03 | 1.39 | 1.08 | 0.72 | 2.50 | 8.64 | 2.51 | 7.38 | — | — | — |
| P/B Ratio | 0.50 | 0.74 | 0.56 | 0.40 | 0.72 | 1.43 | 0.73 | 1.81 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | 44.55 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
OGI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.29 | 0.44 | 0.52 | 2.06 | 8.01 | 3.42 | 7.40 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | 41.37 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 156.95 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
OGI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Organigram Global Inc. earns an operating margin of -34.1%. Operating margins have expanded from -162.7% to -34.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -5.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 3.7% | 3.7% | 29.7% | 23.5% | 21.7% | -35.9% | -65.1% | 60.3% | -215.4% | -61.2% | 86.7% |
| Operating Margin | -34.1% | -34.1% | -22.3% | -162.7% | -29.6% | -116.0% | -167.6% | 6.8% | 293.0% | -206.0% | 20.3% |
| Net Profit Margin | -9.6% | -9.6% | -28.4% | -153.8% | -9.8% | -165.1% | -156.9% | -11.9% | 165.0% | -202.1% | 13.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.4% | -5.4% | -15.7% | -58.9% | -2.9% | -33.5% | -43.5% | -3.7% | 15.3% | -17.1% | 3.2% |
| ROA | -3.7% | -3.7% | -12.9% | -52.4% | -2.5% | -26.9% | -32.2% | -2.6% | 10.4% | -14.8% | 2.5% |
| ROIC | -17.8% | -17.8% | -12.0% | -53.2% | -7.4% | -17.0% | -30.8% | 1.5% | 17.4% | -13.2% | 3.5% |
| ROCE | -16.0% | -16.0% | -11.3% | -60.8% | -8.2% | -20.0% | -37.6% | 1.6% | 19.3% | -16.1% | 3.9% |
OGI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $28M exceeds total debt of $9M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.35 | 0.15 | 0.54 | 0.04 | 0.17 |
| Debt / EBITDA | — | — | — | — | — | — | — | 3.45 | 2.48 | — | 3.69 |
| Net Debt / Equity | — | -0.06 | -0.33 | -0.11 | -0.13 | -0.10 | 0.26 | 0.01 | 0.24 | 0.02 | -0.05 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 0.14 | 1.10 | — | -1.16 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -175.60 | -32.50 | -43.16 | -23.41 | 0.39 | 3.75 | -39.96 | 2.94 |
Net cash position: cash ($28M) exceeds total debt ($9M)
OGI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Organigram Global Inc.'s current ratio of 2.26x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.28x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 6.95x to 2.26x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.26 | 2.26 | 4.92 | 6.95 | 4.01 | 9.92 | 5.85 | 4.47 | 18.06 | 6.72 | 16.62 |
| Quick Ratio | 1.28 | 1.28 | 3.37 | 3.34 | 2.77 | 8.06 | 3.39 | 1.88 | 12.30 | 5.91 | 14.04 |
| Cash Ratio | 0.23 | 0.23 | 2.02 | 1.51 | 1.79 | 7.00 | 2.57 | 1.09 | 11.56 | 5.11 | 13.34 |
| Asset Turnover | — | 0.33 | 0.39 | 0.50 | 0.25 | 0.14 | 0.21 | 0.19 | 0.04 | 0.06 | 0.11 |
| Inventory Turnover | 1.45 | 1.45 | 1.36 | 1.41 | 1.67 | 2.20 | 2.00 | 0.28 | -0.60 | 1.61 | 0.13 |
| Days Sales Outstanding | — | 127.21 | 84.84 | 67.17 | 116.08 | 96.81 | 71.39 | 52.80 | 23.29 | 68.20 | 93.03 |
OGI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Organigram Global Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $128M | $95M | $81M | $85M | $64M | $43M | $35M | $32M | $24M | $15M |
Peer Comparison
Compare OGI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OGIYou | $136M | -9.8 | — | — | 3.7% | -34.1% | -5.4% | -17.8% | — |
 CGC | $372M | -1.6 | — | — | 24.5% | -56.8% | -61.9% | -18.2% | — |
 TLRY | $551M | -0.1 | — | — | 29.3% | -277.9% | -89.1% | -66.2% | — |
 ACB | $181M | -1.9 | — | — | 5.2% | -50.8% | -21.8% | -25.8% | — |
 CRON | $1B | -110.6 | — | 6679.1 | 32.5% | -1.5% | -0.8% | -0.7% | — |
 SNDL | $368M | -33.5 | 8.1 | 9.0 | 27.3% | -0.5% | -1.4% | -0.3% | 3.3 |
 SMG | $4B | 26.2 | 14.1 | 13.7 | 30.6% | 10.5% | — | 13.3% | 5.5 |
 IIPR | $2B | 15.2 | 10.3 | 9.7 | 88.7% | 46.7% | 6.0% | 4.3% | 2.0 |
 LWAY | $389M | 28.6 | 19.0 | — | 27.4% | 7.6% | 17.6% | 17.8% | 0.0 |
 VFF | $218M | 7.1 | 4.0 | 6.9 | 40.6% | 12.7% | 11.3% | 7.4% | 0.9 |
 GRWG | $96M | -4.0 | — | — | 19.8% | -15.0% | -22.1% | -16.1% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
OGI — Frequently Asked Questions
Quick answers to the most common questions about buying OGI stock.
What is Organigram Global Inc.'s P/E ratio?
Organigram Global Inc.'s current P/E ratio is -9.8x. This places it at the 50th percentile of its historical range.
What is Organigram Global Inc.'s ROE?
Organigram Global Inc.'s return on equity (ROE) is -5.4%. The historical average is -35.3%.
Is OGI stock overvalued?
Based on historical data, Organigram Global Inc. is trading at a P/E of -9.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Organigram Global Inc.'s profit margins?
Organigram Global Inc. has 3.7% gross margin and -34.1% operating margin.